Avellino Labs

Granular corneal dystrophy is an eye condition affecting about one in a thousand people with no current cure. Early diagnosis can help with prevention and warn patients when not to have LASIK and other corneal surgeries, resulting in protein formations in the eye and vision loss. Avellino Lab's proprietary and patented DNA sequencing test detects an individual's risk for this genetic condition. Avellino is also working on tests for other rare ophthalmic diseases which can lead to vision loss.

Avellino Labs provides eye care professionals a rapid and inexpensive screening test to further ensure patients cleared for refractive surgery are good candidates. We test for multiple single point gene mutations associated with the most common types of corneal dystrophy, a condition that may not effect vision until triggered by refractive surgery.


Company Growth (employees)
Type
Private
HQ
Menlo Park, US
Founded
2012
Size (employees)
16 (est)+7%
Avellino Labs was founded in 2012 and is headquartered in Menlo Park, US

Avellino Labs Office Locations

Avellino Labs has an office in Menlo Park
Menlo Park, US (HQ)
1505 Adams Dr

Avellino Labs Financials and Metrics

Summary Metrics

Founding Date

2012

Avellino Labs's Web-traffic and Trends

Avellino Labs Online and Social Media Presence

Avellino Labs Company Life and Culture

You may also be interested in